Non-modulating hypertension: Evidence for the involvement of kallikrein/kinin activity associated with overactivity of the renin-angiotensin system. Successful blood pressure control during long-term Na+ restriction

Journal of Hypertension

Volumn 14, Issue 11, 1996, Pages 1287-1291

  Sanchez, Ramiro ^a   Gimenez, María I ^a   Ramos, Felipe ^a   Baglivo, Hugo ^a   Ramirez, Agustin J ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

Author keywords

Hypertension; Non modulation; Plasma renin activity; Sodium; Urinary kallikrein

Indexed keywords

ANGIOTENSIN; KALLIKREIN; KININ; RENIN; SODIUM;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; ESSENTIAL HYPERTENSION; FEMALE; GLOMERULUS; GLOMERULUS FILTRATION; HUMAN; HYPERTENSION; KALLIKREIN URINE LEVEL; KIDNEY PLASMA FLOW; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM RESTRICTION; SODIUM URINE LEVEL; ZONA GLOMERULOSA;

EID: 0029982127     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199611000-00006     Document Type: Article

References (37)

1. MacGregor GA: Sodium is more important than calcium in essential hypertension. Hypertension 1985, 7:628-637.
2. Weinberger NH: Salt sensitivity as a predictor of hypertension. Am J Hypertens 1991, 4:615-616.
3. MacGregor GA: Salt and hypertension. Br J Clin Pharmacol 1986, 21 (suppl 2):123s-128s.
4. Takeshita A, Imaizumi T, Ashihara T, Nakamura M: Characteristics of responses to salt loading and deprivation in hypertensive subjects. Circ Res 1982, 51:457-464.
5. Williams GH, Hollenberg NK: Non-modulating hypertension: a subset of sodium sensitive hypertension. Hypertension 1991, 17 (suppl I): I81-I85.
6. Moore TJ, Williams GH, Dluhy RG, Bavli SZ, Hinathongkan T, Greenfield M: Altered renin-angiotensin-aldosterone relationships in normal renin essential hypertension. Circ Res 1977, 41:167-171.
7. Margolius HS: Kallikreins and kinins: some unanswered questions about system, characteristics and roles in human disease. Hypertension 1995, 26:221-229.
8. Sanchez RA, Marco E, Gilbert HB, Raffaele P, Brito M, Gimenez M, Moledo LI: Natriuretic effect and changes in renal haemodynamics induced by enalapril in essential hypertension. Drugs 1985, 30 (suppl 1):49-58.
9. Bailie MD, Barbour JA: Effect of inhibition of peptidase activity on the distribution of intrarenal blood flow. Am J Physiol 1975, 228:850-853.
10. Stein JH, Congbalay RC, Karsh DL, Osgood RW, Ferris RF: The effect of bradykinin on proximal tubular sodium reabsorption in the dog: evidence for functional nephron heterogeneity. J Clin Invest 1972, 51: 1709-1721.
11. Roman R, Kaldusnki M, Scicli A, Carretero O: Influence on kinins and angiotensin II on the regulation of papillary blood flow. Am J Physiol 1988, 255:F690-F698.
12. Carretero OA, Scicli AG: Local hormonal factors (intracrine, autocrine and paracrine) in hypertension. Hypertension 1991, 18 (suppl 1): 159-169.
13. Carretero OA, Scicli A, Piwonska A, Koch J: Urinary kallikrein in rats bred for susceptibility and resistance to the hypertensive effect of salt and in New Zealand genetically hypertensive rats. Mayo Clin Proc 1977, 52:465-467.
14. Margolius HS: Tissue kallikreins and kinins regulations and roles in hypertensive and diabetic diseases. Annu Rev Pharmacol 1989, 29: 343-364.
15. Berry TD, Hasstedt SJ, Hunt SC, Wu LL, Smith JB, Ash KO, et al.: A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension 1989, 13:3-8.
16. Ramirez AJ, Gimenez MI, Gallo J, Marcó EJ, Sánchez RA: Renal sodium handling abnormalities in hypertensive and normotensive patients with a family history of hypertension. J Hypertens 1989, 7 (suppl 7): S19-S20.
17. Schnurr E, Lahma W, Kuppers H: Measurements of renal clearance in inulin and PAH in the steady state without urine collection. Clin Nephrol 1980, 13:26-29.
18. Smith H, Goldring W, Chasis H: The measurement of the tubular excretory mass, effective blood flow and filtration rate in the normal kidney. J Clin Invest 1938, 17:263-266.
19. Deutsch E: Mitteilung zur Nierenclearance: Eine einfache Methode zur quantitativen Bestimmung der Lavelose und des Inulins im Harn und im Serum. Klin Med 1949, 4:81-85.
20. Sanchez RA, Cavarra O, Brea S, Marco EJ, Ravera M, Moledo LI: Actividad reninica plasmática en la hipertensiȯn arterial esencial. Medicina (Buenos Aires) 1979, 39:171-179.
21. Grunfeld B, Gimenez MI, Simsolo R, Becu L: Changes in urinary kallikrein in hypertensive and in uniphrectomized children [abstract]. Hypertension 1987, 9:555.
22. Madeddu P, Oppes M, Rubattu S, Tonolo GC, Dessi-Fulgheri P, Glorioso N: Prokallikrein and kallikrein inhibition in human urine. J Hypertens 1988, 3 (suppl 3):S83-S85.
23. Dessi-Fulgheri P, Espinosa E, Zingaretti O, Guazzarotti F, Sarzani R, Pupita G, et al.: Urinary kallikrein excretion and blood pressure response to angiotensin converting enzyme inhibitors and calcium antagonists in hypertensive patients. J Hypertens 1993, 11:725-730.
24. Williams GH, Hollenberg NK: Are non-modulating patients with essential hypertension a distinct subgroup? Am J Med 1985, 79 (suppl 3C):3-9.
25. Bhoola KD, Figueroa CD, Worthy K: Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992, 44:1-80.
26. Hess JF, Borkowsky JA, Young GS, Strader CD, Ransom RW: Cloning and pharmacological characterization of a human bradykinins (BK-2) receptor. Biochem Biophys Res Commun 1992, 184:260-268.
27. Ferri C, Bellini C, Carlomagno A, Perrone A, Santucci A: Urinary kallikrein and salt sensitivity in essential hypertensive males. Kidney Int 1994, 46:780-788.
28. McGarvey ST, Zinner SH, Margolius HS: Urinary kallikrein and blood pressure in infants and children. In Renal Function, Hypertension and Kallikrein-Kinin Systems. Edited by Limura O, Margolius HS. Tokyo: Hokusen-Sha; 1988:161-168.
29. Bellini C, Ferri C, Piccoli A, Carlomagno A, Di Francesco L, Bonavita MS, et al.: The influence of salt sensitivity on the blood pressure response to exogenous kallikrein in essential hypertensive patients. Nephron 1993, 65:28-35.
30. Berri TD, Hasstedt SJ, Hunt SC, Wu LL, Smith JB: A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension 1988, 13:3-8.
31. Cacofeiro V, Maeso R, Rodrigo E, Navarro J, Ruilope LM, Lahera V: Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension. Hypertension 1995, 26:236-243.
32. Watkin DM, Froeb HF, Hatch FT, Gutman AB: Effects of diet in essential hypertension. II. Results with unmodified Kampner rice diet in fifty hospitalised patients. Am J Med 1950, 9:441-493.
33. Morgan T, Gillies A, Morgan G, Adams W, Wilson M, Carney S: Hypertension treated by salt restriction. Lancet 1978, i:227-230.
34. Beilin LJ: Non-pharmacological management of hypertension: optimal strategies for reducing cardiovascular risk. J Hypertens 1994 12 (suppl 10):571-581.
35. Ciraghi HM, Ibrahim MM, Jaffa AA, Myfield KK, Margolius HS: Rat renal interstitial bradykinin, prostaglandin E2 and cyclic guanosyne 3′5′ monophosphate: effects of altered sodium intake. Hypertension 1994, 23:1068-1070.
36. Buscands JL, Pecher C, Rouaud S, Emond C, Tack JL, Bastie MJ, et al.: Evidence for existence of two distinct bradykinin receptors on rat mesangial cells. Am J Physiol 1993, 264:F548-F556.
37. Ciragy HM, Jaffa AA, Margolius HS: Stimulation of renal interstitial kinins by sodium depletion. Am J Hypertens 1984, 6:863-866.